Oculis Holding Ag · NASDAQ:OCS
Oculis — Investor Presentation (September 2026)
43 slides from Oculis's investor presentation, September 2026
Slide 1: Visionary Innovation
Visionary Innovation September 2026
Slide 2: Safe Harbor Statements
Safe Harbor Statements Cautionary note on forward-looking statements These slides and any accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “may,” “might,” “will,” “sh
Slide 3: Oculis (Nasdaq / XICE: OCS)
Oculis (Nasdaq / XICE: OCS) Registrational programs for neuro-ophthalmic and ophthalmic indications target multi-billion-dollar market opportunities • Global biopharma Nasdaq-listed company with two registrational-stage candidates targeting a market opportunity of over $25B • Licaminlimab (Precision
Slide 4: Upcoming Value-Driving Milestones Across Our Targeted Registrational Programs
Upcoming Value-Driving Milestones Across Our Targeted Registrational Programs Candidate Phase 1 Phase 2 Phase 3 Upcoming Anticipated Value Catalysts OPHTHALMOLOGY Licaminlimab Genotype-based PREDICT-1 TLR around year-end 2026 development Dry Eye Disease program NEURO-OPHTHALMOLOGY Breakthrough Thera
Slide 5: Licaminlimab: Dry Eye Disease
Licaminlimab Dry Eye Disease 5
Slide 6: Licaminlimab is a Novel Anti-TNFα Eye Drop for Ocular Inflammation with Clinically Proven MoA
IgG Illu Licaminlimab is a Novel Anti-TNFα Eye Drop for Ocular Inflammation no str ati o with Clinically Proven MoA f fr ag m en t tec hn olo gy Topical Biologic Candidate Innovative Antibody Fragment Technology Fa b Re gi o ne ns t utr ha ali t b Licaminlimab is an anti-TNFα antibody fragment speci
Slide 7: Large Unsatisfied Market with Only 13% of Patients Experiencing Lasting Relief After 12 Months
Large Unsatisfied Market with Only 13% of Patients Experiencing Lasting Relief After 12 Months with Current Treatments1 2024 Dry Eye Rx drug market in Driven by trial and error G7 countries2 and U.S. Rx split3 with significant unmet needs Others 13% 53% – 70% discontinued after a single script Disco
Slide 8: Licaminlimab: Three Positive DED Phase 2 Trials Completed
Licaminlimab: Three Positive DED Phase 2 Trials Completed with Consistent Results and Potential for Precision Medicine Approach Phase 2 Randomized Controlled Consistent positive results across studies and Studies in DED unique genotype-based development opportunity DED#1 Symptoms 01 Meaningful and r
Slide 9: DED#2: Licaminlimab (OCS-02) Phase 2a Trial Evaluating Symptoms in DED
DED#2: Licaminlimab (OCS-02) Phase 2a Trial Evaluating Symptoms in DED Phase 2a study design Efficacy endpoints Safety Assessments • Randomized, double-blind, vehicle- • Primary endpoint: Change from baseline • Ophthalmic evaluation & adverse controlled, 6-week multi-center trial in global ocular di
Slide 10: Licaminlimab (OCS-02) Phase 2a Trial Evaluating Symptoms in DED
Licaminlimab (OCS-02) Phase 2a Trial Evaluating Symptoms in DED Statistically significant reduction in ocular discomfort and greater percentage of high responders with Licaminlimab (OCS-02) vs. vehicle Primary Endpoint - Mean Change In Global Secondary endpoint – Percentage of high Ocular Discomfort
Slide 11: DED#3: RELIEF Phase 2b in Signs of DED
DED#3: RELIEF Phase 2b in Signs of DED Designed to identify the most relevant endpoint in signs and assess TNFR1 genetic biomarker in signs in DED Phase 2b study design Primary Objective Patient Population • Randomized, masked, vehicle- • Evaluate efficacy and safety in • Moderate to severe corneal
Slide 12: Licaminlimab (OCS-02) Effect on Inferior Corneal Staining
Licaminlimab (OCS-02) Effect on Inferior Corneal Staining Meaningful treatment effect in the full population and more pronounced in TNFR1-related genotype group Pre- to Post-CAE change from baseline at Day 43 Difference in means of OCS-02 vs Vehicle; (CI)* Treatment Effect Favors Full Population TNF
Slide 13: Licaminlimab Phase 2b: Effect on Inferior Corneal Staining in TNFR1 Genetic Biomarker Population
Licaminlimab (OCS-02) in Phase 2b: Effect on Inferior Corneal Staining in TNFR1 Genetic Biomarker Population Mean change from baseline (Pre- to Post-CAE) Favors Licaminlimab Licaminlimab Vehicle Difference P < 0.05* Visit (N = 12) (N = 11) (90% Cl) (-1.165, -0.017) Baseline 1.46 1.23 -0.38 Day 15 -0
Slide 14: Opportunity for Highly Differentiated Product Profile
Opportunity for Highly Differentiated Product Profile Licaminlimab (OCS-02) has potential to address key unmet needs and transform the treatment paradigm of DED Unmet Needs in DED1 Licaminlimab (OCS-02) Meaningful treatment effect in both signs and symptoms with a New MoA targeting both signs and sy
Slide 15: Licaminlimab First Genotype-based Development to Drive Precision Medicine in DED
Licaminlimab First Genotype-based Development to Drive Precision Medicine in DED Registration Program Started with PREDICT-1 Trial in Q4 2025 Phase 2/3 Study Design Key Efficacy Endpoints Study Population • Randomized, multicenter, double-masked, Primary endpoint: • TNFR1 genotype: ~2/3 positive veh
Slide 16: Privosegtor: Optic Neuritis
Privosegtor Optic Neuritis 16
Slide 17: Privosegtor Product Overview
Privosegtor Product Overview A potential first-in-class neuroprotective therapy for the optic nerve and CNS Privosegtor Novel Small Crosses Blood-brain Prevents Neuronal Neuroprotective Molecule and Retinal Barriers Apoptosis Platform Peptoid-based small Privosegtor penetrates both Promotes neuro-ax
Slide 18: Privosegtor Is a Novel Neuroprotective Candidate with Broad Potential for Neuro-axonal Diseases
Privosegtor Is a Novel Neuroprotective Candidate with Broad Potential for Neuro-axonal Diseases • Peptoid small molecule that crosses blood brain and retinal barriers Neuron • Developed using a hybrid drug discovery approach that combined rational medicinal chemistry design with phenotypic drug sele
Slide 19: Privosegtor | Pre-clinical Evidence of Neuroprotective Activity (1/2)
Privosegtor | Pre-clinical Evidence of Neuroprotective Activity (1/2) Compelling data showing prevention of RGC damage in glaucoma, acute optic neuritis and functional improvement in EAE models OCS-05, IVT and topical, shown to prevent OCS-05 shown to promote improvement of Acute optic neuritis mode
Slide 20: Privosegtor | Pre-clinical Evidence of Neuroprotective Activity (2/2)
Privosegtor | Pre-clinical Evidence of Neuroprotective Activity (2/2) Promotes axonal sparing and reduces demyelination in model of acute optic neuritis Assessment after 5-days of treatment1 Reduced Optic Nerve Axonal Loss 2.00 Reduced Optic Nerve Demyelination 2.00 1.70 1.80 1.80 % Efficacy 1.60 %
Slide 21: Opportunity to Change Standard of Care for Optic Neuropathies
Opportunity to Change Standard of Care for Optic Neuropathies Two Optic Neuropathies Under Same IND Estimated U.S. Patients per Year1-3 Estimated U.S. Market Potential Optic Neuritis NAION >$7B • Rare diseases without approved >30K >30K • therapies often under-diagnosed Price analogs: $100k-$400k pe
Slide 22: Optic Neuritis, an Acute Inflammation of the Optic Nerve which Can Lead to Permanent Visual Impairment
Optic Neuritis, an Acute Inflammation of the Optic Nerve which Can Lead to Permanent Visual Impairment Orphan indication with Acute inflammation of the optic nerve ~ 65k patients per year (US/EU)1,2 impacting retinal ganglion cells and leading to vision loss • Type of neuropathy causing vision loss
Slide 23: Successful Phase 2 ACUITY Trial Investigated Safety and Efficacy of Privosegtor in Optic Neuritis
Successful Phase 2 ACUITY Trial Investigated Safety and Efficacy of Privosegtor in Optic Neuritis Study Design Key Endpoints Study Population • Randomized, double-masked, placebo- Primary: Safety • Unilateral optic neuritis with a controlled study demyelinating origin Secondary: • Multi-center, 6-mo
Slide 24: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics1 Privosegtor + steroid Placebo + steroid 3 mg/kg/day (N = 14) (N = 15) Age, mean (SD), years 33.7 (9.8) 32.7 (10.3) Female, n (%) 9 (60.0) 10 (71.4) GCIPL thickness, mean (SD), µm 89.3 (8.3) 84.3 (13.8) RNFL thickness, mean (SD), µm 104.6 (13.1) 115.
Slide 25: Privosegtor Arm Achieved Clinically Meaningful and Sustained Improvement in Visual Function
Patients in the Privosegtor 3mg/kg/day Arm Achieved Clinically Meaningful and Sustained Improvement in Visual Function1 2.5% ETDRS LCVA in the Affected Eye: MMRM, LS Mean Change From Baseline, mITT FUNCTION LCVA: Low-contrast visual acuity is +18 ETDRS Letters +15 ETDRS Letters often affected in pat
Slide 26: More Patients Achieved ≥15 and ≥30 ETDRS LCVA Letter Improvement at Month 3
More Patients Achieved ≥15 and ≥30 ETDRS LCVA Letter Improvement with Privosegtor 3 mg/kg/day vs Placebo at Month 3 (Post Hoc Analysis)1 Proportion of Participants with ≥15 LCVA Proportion of Participants with ≥30 LCVA Letter Gain from Baseline1 Letter Gain from Baseline1 100% 100% ≥15 LCVA letter g
Slide 27: Privosegtor Arm Showed a Robust LCVA Improvement Across all Subgroups
Privosegtor Arm Showed a Robust LCVA Improvement Across all Subgroups and Maintained through Month 61 LCVA letters subgroup analyses of Privosegtor 3mg + steroid vs placebo + steroid LS Mean LS Mean difference difference Subgroup LSM difference at month 3 (P-value*) LSM difference at month 6 (P-valu
Slide 28: Functional Improvement Correlated with Significant Preservation of Neurons in the Retina (RGCs)
Functional Improvement Correlated with Significant Preservation of Neurons in the Retina (RGCs)1 GCIPL Thickness in the Affected Eye: MMRM, LS Mean Change From Baseline, mITT ANATOMY 5 GCIPL and RNFL: layers of the retina GCIPL Thickness Change, LS Mean (SE) measured by OCT to monitor Placebo + ster
Slide 29: Functional Improvement Correlated also with Significant Preservation of Axons (RNFL Thickness)
Functional Improvement Correlated also with Significant Preservation of Axons (RNFL Thickness)1 RNFL Thickness in the Affected Eye: MMRM, LS Mean Change from Baseline, mITT ANATOMY 0 GCIPL and RNFL: layers of the retina Placebo + steroid (N = 14) measured by OCT to monitor Privosegtor (OCS-05) 3mg/k
Slide 30: Neuroprotective Benefits Also Observed in Biological Sign of Neuronal and Axonal Death
Neuroprotective Benefits with Privosegtor Also Observed in Biological Sign of Neuronal and Axonal Death1 Mean Plasma Neurofilaments Over Time, mITT BIOLOGY Neurofilaments: Released into CSF pg/mL and blood as a result of axonal and neuronal death2 15 14.6 14.5 Mean (SE) 11.7 -47% 10 8.6 *P = 0.046 9
Slide 31: Safety Profile Reported in ACUITY Phase 2 Trial
Safety Profile Reported in ACUITY Phase 2 Trial Showed No AEs Leading to Drug Withdrawal or Study Discontinuation • No AEs leading to drug withdrawal or study discontinuation • No drug-related serious adverse events (SAEs) Event, n (%) Privosegtor + steroid Placebo + 2 mg/kg/day 3 mg/kg/day Pooled s
Slide 32: PIONEER-1 Registrational Trial Aligned with FDA under Special Protocol Assessment
PIONEER-1 Registrational Trial Aligned with FDA under Special Protocol Assessment Privosegtor has potential to be first neuroprotective medicine in Optic Neuritis Study Design Key Efficacy Endpoints Study Population • Randomized, multicenter, double-masked, Primary: • All comers: including MS and no
Slide 33: Privosegtor Driving Multiple Anticipated Milestones in Next 18 Months
Privosegtor Driving Multiple Anticipated Milestones in Next 18 Months Three Registrational PIONEER-1 in optic neuritis enrollment completion 2027 trials in optic neuritis and NAION PIONEER-2 in ON and PIONEER-3 in NAION trials initiation Q4 2026 Acute MS relapses IND submission planned Q4 2026 First
Slide 34: Privosegtor: Acute Multiple Sclerosis (MS) Relapses
Privosegtor Acute Multiple Sclerosis (MS) Relapses 34
Slide 35: Optic Neuritis a Solid PoC in MS and Beyond
Optic Neuritis a Solid PoC in MS and Beyond Phase 2 ACUITY trial established Privosegtor’s neuroprotective potential in acute optic neuritis, the same biology underpins every acute MS relapse PoC Phase 2 ACUITY Trial Same Biology Acute optic neuritis · Privosegtor 3 mg/kg Optic neuritis is a typical
Slide 36: MS is a Major Cause of Neurological Disability in Young Adults
MS is a Major Cause of Neurological Disability in Young Adults and Affects ~850,000 Individuals in the United States Alone1-5 MS at a Glance Worldwide Prevalence of MS2 MS is an autoimmune-mediated neurodegenerative disease of the central nervous system characterized by inflammatory demyelination wi
Slide 37: MS is One of the Most Common Causes of Neurological Disability Affecting Young Adults
MS is One of the Most Common Causes of Neurological Disability Affecting Young Adults1 High prevalence of Large and growing Existing therapies reduce relapse multiple sclerosis market driven by frequency however relapse- worldwide2-5 immuno-modulators associated worsening remains Estimated Multiple
Slide 38: Acute MS Relapses Share the Same Inflammatory Demyelinating Pathophysiology
Whether Inaugural or Recurrent, Acute MS Relapses Share the Same Inflammatory Demyelinating Pathophysiology Acute MS Relapses1-3 Characterized by focal or multifocal inflammatory demyelination leading to neuronal damage, lasting >24h. Clinical presentation is heterogeneous and depends on the locatio
Slide 39: By Treating Relapses, We May Be Able to Reduce RAW
By Treating Relapses, We May Be Able to Reduce RAW • RAW: Relapse-Associated Relapsing Remitting Multiple Sclerosis Worsening • Effective neuroprotection in Functional Impairment Relapse relapses could translate to reduced accumulation of Relapse disability due to relapses over time 1-4 Relapse RAW
Slide 40: Conclusion
Conclusion 40
Slide 41: Explore Expand Advance
Oculis Pipeline Development Strategic Evolution Explore Expand Potential for Privosegtor in multiple additional neuro-axonal diseases Privosegtor in neuro- ophthalmology and beyond • NAION Advance • MS relapses ~$50B Privosegtor neuroprotection in optic neuritis Licaminlimab precision >$25B medicine
Slide 42: Upcoming Value-Driving Milestones Across Our Targeted Registrational Programs
Upcoming Value-Driving Milestones Across Our Targeted Registrational Programs Candidate Phase 1 Phase 2 Phase 3 Upcoming Anticipated Value Catalysts OPHTHALMOLOGY Licaminlimab Genotype-based PREDICT-1 TLR around year-end 2026 development Dry Eye Disease program NEURO-OPHTHALMOLOGY Breakthrough Thera
Slide 43: Thank you
“Sculis Visionary Innovation